Experimental cell therapy takes aim at Hard-to-Treat cancers

NCT ID NCT06484790

Recruiting now Disease control Sponsor: Ting Deng Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D). The treatment involves collecting a patient's own immune cells, engineering them to recognize and attack cancer cells carrying the mutation, and infusing them back. Only 9 participants will be enrolled to evaluate safety and anti-tumor activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: T cell receptor gene-engineered T cells targeting KRAS G12V or G12D mutations
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors with specific KRAS mutations that currently have few alternatives.
What could go wrong: This is a very early Phase 1 trial with only 9 participants, so safety and effectiveness are not yet known. The therapy may not shrink tumors or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR, SOLID

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.